Suppr超能文献

载脂蛋白 E 基因型对阿尔茨海默病区域性病理学的影响。

The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease.

机构信息

The Cleo Robert Center for Clinical Research, Banner Sun Health Research Institute, Sun City, AZ, USA.

出版信息

BMC Neurol. 2013 May 11;13:44. doi: 10.1186/1471-2377-13-44.

Abstract

BACKGROUND

Carriers of the ApoE ϵ4 allele are at a greater risk for developing Alzheimer's disease (AD) and those who do develop AD tend to have a much greater neuropathological disease burden. Although several studies have shown significant differences in AD pathology among ϵ4 carriers and non-carriers, few have characterized these differences in terms of brain region and neuropathological score frequency.

METHODS

566 pathologically-confirmed AD cases who were followed prospectively with antemortem dementia diagnoses (312 ApoE ϵ4 carriers and 254 ApoE ϵ4 non-carriers) were compared on the frequencies of neuropathological frequency scores (none, sparse, moderate, frequent) among several different brain regions (frontal, temporal, parietal, hippocampal, and entorhinal) using the CERAD scoring system. Pathology score frequencies were analyzed by carrier status (ϵ4 carrier vs. ϵ4 non-carrier) and by genotype (2/3, 3/3, 2/4, 3/4, 4/4). Both analyses investigated pathology score frequencies among different brain regions (frontal, temporal, parietal, hippocampal, and entorhinal).

RESULTS

ϵ4 carriers had a significantly lower age at death (p <0.001) and significantly higher Braak scores (p <0.001) than ϵ4 non-carriers. Genotype comparison revealed that plaque and tangle pathologies increased in the following pattern, 2/3<3/3<2/4<3/4<4/4, for several brain regions. When stratified by age and ApoE ϵ4 carrier status, ϵ4 carriers tended to have significantly more frequent scores across most cortical areas. However, non-carriers age 90 and older tended to have greater plaque pathology than carriers. For tangle pathology, ϵ4 carriers tended to have significantly more "frequent" scores than non-carriers, except for the hippocampal and entorhinal areas in individuals age 90 and older.

CONCLUSIONS

ApoE ϵ4 carriers had a significantly higher percentage of "frequent" scores for plaques and tangles when compared to ApoE ϵ4 non-carriers for several brain regions. However, ϵ4 non-carriers age 90 and older tended to have less plaque and tangle pathology in certain brain regions. These results demonstrate that AD pathology may manifest itself differently based on ApoE genotype and suggest that ApoE carriers and non-carriers may have different patterns of AD neuropathology location and density.

摘要

背景

载脂蛋白 E ε4 等位基因携带者患阿尔茨海默病(AD)的风险更高,而那些确实患有 AD 的患者往往具有更大的神经病理学疾病负担。尽管有几项研究表明 ε4 携带者和非携带者之间的 AD 病理学存在显著差异,但很少有研究从脑区和神经病理学评分频率的角度来描述这些差异。

方法

对 566 例经病理证实的 AD 病例进行前瞻性随访,这些病例生前均有痴呆诊断(312 例载脂蛋白 E ε4 携带者和 254 例载脂蛋白 E ε4 非携带者),使用 CERAD 评分系统比较了几种不同脑区(额、颞、顶、海马和内嗅皮质)的神经病理学评分频率(无、稀疏、中度、频繁)。根据载脂蛋白 E 基因型(2/3、3/3、2/4、3/4、4/4)和载脂蛋白 E 状态(载脂蛋白 E 携带者与载脂蛋白 E 非携带者)对病理评分频率进行了分析。这两种分析均研究了不同脑区(额、颞、顶、海马和内嗅皮质)的病理评分频率。

结果

ε4 携带者的死亡年龄显著较低(p<0.001),Braak 评分显著较高(p<0.001)。与 2/3 相比,载脂蛋白 E 基因型比较显示斑块和缠结病理学在以下模式下增加:3/3<2/4<3/4<4/4,多个脑区均如此。当按年龄和载脂蛋白 E ε4 携带状态分层时,ε4 携带者在大多数皮质区域的评分频率显著较高。然而,90 岁及以上的非携带者的斑块病理较携带者更为严重。对于缠结病理学,ε4 携带者的“频繁”评分显著高于非携带者,除了 90 岁及以上个体的海马和内嗅皮质区域。

结论

与载脂蛋白 E ε4 非携带者相比,载脂蛋白 E ε4 携带者在多个脑区的斑块和缠结评分中“频繁”评分的比例显著更高。然而,90 岁及以上的非携带者在某些脑区的斑块和缠结病理较少。这些结果表明,AD 病理学可能根据载脂蛋白 E 基因型表现出不同的特征,并表明载脂蛋白 E 携带者和非携带者可能具有不同的 AD 神经病理学位置和密度模式。

相似文献

1
The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease.
BMC Neurol. 2013 May 11;13:44. doi: 10.1186/1471-2377-13-44.
2
Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.
Curr Alzheimer Res. 2013 Jul;10(6):654-9. doi: 10.2174/15672050113109990006.
3
Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease.
Virchows Arch. 2015 Aug;467(2):225-35. doi: 10.1007/s00428-015-1772-1. Epub 2015 Apr 22.
5
APOE ε4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.
Alzheimers Res Ther. 2022 Mar 30;14(1):47. doi: 10.1186/s13195-022-00992-y.
6
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.
Lancet Neurol. 2011 Sep;10(9):785-96. doi: 10.1016/S1474-4422(11)70156-9. Epub 2011 Jul 27.
10
Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians.
Neurosci Lett. 1995 Dec 1;201(1):45-7. doi: 10.1016/0304-3940(94)12126-b.

引用本文的文献

1
Machine learning quantification of Amyloid-β deposits in the temporal lobe of 131 brain bank cases.
Acta Neuropathol Commun. 2024 Aug 17;12(1):134. doi: 10.1186/s40478-024-01827-7.
2
Early- and Late-Onset Alzheimer's Disease: Two Sides of the Same Coin?
Diseases. 2024 May 22;12(6):110. doi: 10.3390/diseases12060110.
3
Multiple system atrophy with amyloid-β-predominant Alzheimer's disease neuropathologic change.
Brain Commun. 2024 Apr 17;6(3):fcae141. doi: 10.1093/braincomms/fcae141. eCollection 2024.
4
Apolipoprotein E isoform does not influence trans-synaptic spread of tau pathology in a mouse model.
Brain Neurosci Adv. 2023 Aug 17;7:23982128231191046. doi: 10.1177/23982128231191046. eCollection 2023 Jan-Dec.
5
Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy.
Acta Neuropathol Commun. 2023 Jun 19;11(1):99. doi: 10.1186/s40478-023-01581-2.
6
Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches.
Cell Mol Neurobiol. 2023 Oct;43(7):3115-3136. doi: 10.1007/s10571-023-01365-1. Epub 2023 May 25.
7
APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression.
Sci Transl Med. 2022 Nov 16;14(671):eabl7646. doi: 10.1126/scitranslmed.abl7646.
8
Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.
Methods Mol Biol. 2022;2547:275-387. doi: 10.1007/978-1-0716-2573-6_13.

本文引用的文献

1
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006312. doi: 10.1101/cshperspect.a006312.
3
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.
Lancet Neurol. 2011 Sep;10(9):785-96. doi: 10.1016/S1474-4422(11)70156-9. Epub 2011 Jul 27.
4
Apolipoprotein E in Alzheimer's disease and other neurological disorders.
Lancet Neurol. 2011 Mar;10(3):241-52. doi: 10.1016/S1474-4422(10)70325-2.
6
Amyloid load in nondemented brains correlates with APOE e4.
Neurosci Lett. 2010 Apr 12;473(3):168-71. doi: 10.1016/j.neulet.2010.02.016. Epub 2010 Feb 12.
7
ApoE promotes the proteolytic degradation of Abeta.
Neuron. 2008 Jun 12;58(5):681-93. doi: 10.1016/j.neuron.2008.04.010.
8
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007.
Cell Tissue Bank. 2008 Sep;9(3):229-45. doi: 10.1007/s10561-008-9067-2. Epub 2008 Mar 18.
9
The effect of APOE genotype on clinical phenotype in Alzheimer disease.
Neurology. 2006 Aug 8;67(3):526-7. doi: 10.1212/01.wnl.0000228222.17111.2a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验